The Clinical Conundrum in Managing Preterm Birth: Balancing Historical Trial Results, Society Guidelines, and Clinical Experience with a Contradictory Trial Outcome

This activity is designed to meet the educational needs of Maternal-Fetal Medicine Specialists, Ob/Gyns, Nurse Practitioners, Physician Assistants, and Certified Nurse Midwives

Activity Information


Credits: 0.25 AMA PRA Category 1 Credits
Released: 01/30/2020
Valid until: 01/30/2021



Baha M. Sibai, MD
Professor of Ob/Gyn
Director, MFM Fellowship Program
Department of Obstetrics, Gynecology and Reproductive
Sciences, The University of Texas Medical School at Houston
Houston, TX


To receive CME credit, please read the article and go to to access the posttest and evaluation.


Reviewers/Content Planners/Authors:

  • Sean T. Barrett has nothing to disclose.
  • Barry A. Fiedel, PhD, has nothing to disclose.
  • Amanda Hilferty has nothing to disclose.
  • Robert Schneider, MSW, has nothing to disclose.
  • Baha M. Sibai, MD, has nothing to disclose.

Learning Objectives:

After participating in this educational activity, participants should be better able to:

  1. Incorporate strategies for providing optimal clinical management to women at risk for preterm birth, based on established SMFM, ACOG, and ACNM recommendations.
  2. Define the historical role of 17-OHPC in the management of preterm birth.
  3. Identify clinical trial factors—patient populations, healthcare systems—that can influence the results of a clinical trial.

Accreditation and Credit Designation Statements:

Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Global Learning Collaborative designates this enduringmaterial for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:

This activity is supported by an independent educational grant from AMAG Pharmaceuticals, Inc.